Palvella Therapeutics, Inc. (PVLA)

Palvella Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	83.6	7.35	16.05
Cash & Short-Term Investments	83.6	7.35	16.05
Cash Growth	1037.44%	-54.21%	-
Prepaid Expenses	4.63	0.2	0.47
Total Current Assets	88.23	7.55	16.52
Total Assets	88.23	7.55	16.52
Accounts Payable	-	0.94	3.18
Accrued Expenses	-	1.26	2.44
Other Current Liabilities	12.04	0.17	0.16
Total Current Liabilities	12.04	2.36	5.78
Long-Term Debt	-	8.05	32.42
Other Long-Term Liabilities	13.59	1.01	1.5
Total Liabilities	25.63	11.43	39.7
Common Stock	62.61	-	-
Additional Paid-In Capital	-	1.82	1.22
Retained Earnings	-	-76.3	-94.99
Total Common Equity	62.61	-74.48	-93.78
Shareholders' Equity	62.61	-3.88	-23.17
Total Liabilities & Equity	88.23	7.55	16.52
Total Debt	-	8.05	32.42
Net Cash (Debt)	83.6	-0.7	-16.36
Net Cash Per Share	37.56	-0.12	-2.86
Filing Date Shares Outstanding	-	5.72	5.72
Total Common Shares Outstanding	-	5.72	5.72
Working Capital	76.2	5.19	10.74
Book Value Per Share	-	-13.02	-16.40
Tangible Book Value	62.61	-74.48	-93.78
Tangible Book Value Per Share	-	-13.02	-16.40

Updated Dec 16, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q